[ET Net News Agency, 28 December 2021] CStone Pharmaceuticals (02616) said the new drug
application (NDA) of first-in-class precision therapy AYVAKIT (avapritinib) has been
approved in Hong Kong, China for the treatment of adult patients with unresectable or
metastatic gastrointestinal (GI) stromal tumour (GIST) harbouring a PDGFRA D842V mutation.
The drug is the first precision therapy approved in Hong Kong, China for the treatment of
patients with PDGFRA D842V mutant GIST.
Discovered by CStone's partner Blueprint Medicines Corporation (NASDAQ: BPMC) (Blueprint
Medicines), AYVAKIT is a potent, selective and orally available inhibitor of KIT and
PDGFRA mutant kinases. CStone has an exclusive collaboration and licence agreement with
Blueprint Medicines for the development and commercialization of AYVAKIT and certain other
drug candidates in mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines
retains development and commercial rights for AYVAKIT in the rest of the world. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02616 CSTONE PHARMA-B
Nominal 
0.860 +0.030 (+3.614%) Others
28/12/2021 09:15
CStone Pharma (02616) gets new drug application approval
| Remark: | Real time quote last updated: 23/04/2024 16:53 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |